Abstract: Provided herein are methods of treating a solid malignant tumor using antigen-specific T cells and methods of managing tumor flare in treatment of a solid malignant tumor using antigen-specific T cells. The methods provided herein improve the safety of treatment by informing the patient about the potential risks for tumor flare, telling the patient to contact his or her physician if tumor swelling occurs, counseling a patient with Waldeyer's ring lymphadenopathy to contact his or her physician if shortness of breath or stridor occurs, or grading and managing tumor flare developed in the patient.
Abstract: The present invention provides means and methods for treating Interleukin 18 (IL-18)-associated diseases and disorders. In particular, the present invention discloses antibodies specific for free IL-18 and IL-18 Binding Protein (IL-18BP) for use in such treatments and for the diagnosis of the diseases and disorders.
Abstract: Provided are T cell receptors (TCR) and TCR variable regions that can selectively bind the T-cell leukemia/lymphoma 1 (TCL1) oncoprotein. The TCR may be utilized in various therapies, such as autologous TCL1-TCR adoptive T cell therapy, to treat a cancer, such as a B-cell malignancy or a solid tumor expressing TCL1. Methods for expanding a population of T cells that target TCL1 are also provided.
Type:
Grant
Filed:
January 9, 2019
Date of Patent:
March 5, 2024
Assignee:
Board of Regents, The University of Texas System
Inventors:
Jinsheng Weng, Kelsey Moriarty, Sattva S. Neelapu
Abstract: The current invention provides monocytic cells transfected with chimeric antigen receptor (CAR) to selectively home to tumors and upon homing differentiate into dendritic cells capable of activating immunity which is inhibitory to said tumor. In one embodiment of the invention, monocytic cells are transfected with a construct encoding an antigen binding domain, a transcellular or structural domain, and an intracellular signaling domain. In one specific aspect of the invention, the antigen binding domain interacts with sufficient affinity to a tumor antigen, capable of triggering said intracellular domain to induce an activation signal to induce monocyte differentiation into DC.
Type:
Grant
Filed:
October 27, 2022
Date of Patent:
March 5, 2024
Assignee:
MYELOID THERAPEUTICS, INC.
Inventors:
Samuel C. Wagner, Thomas E. Ichim, Julia S. Szymanski, Santosh Kesari, Amit N. Patel, Boris Minev
Abstract: Described herein is a method for treating or restoring loss of hearing and balance in a subject in need thereof. In certain aspects, the disclosed method is comprised of transplanting a humanized otocyst to a target delivery site in the subject. According to certain aspects, the otocyst is obtained from a humanized non-human mammal embryo. In certain exemplary aspects, the non-human mammal is a pig. In certain embodiments, prior to transplantation, the otocyst is cultured in a species-specific tissue culture buffer.
Abstract: The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.
Abstract: The methods and compositions described herein relate to producing, expanding, enriching, and/or maintaining hematopoietic stem cells ex vivo by treating the cells with an agent(s) that exhibits two or more activities selected from modulation of histone methylation; inhibition of TGF? signaling; inhibition of p38 signaling; activation of canonical Wnt signaling; and modulation of histone acetylation. In some embodiments, the technology described herein relates to transplantation of hematopoietic stem cells.
Type:
Grant
Filed:
April 21, 2020
Date of Patent:
February 6, 2024
Inventors:
Derrick J. Rossi, Wataru Ebina, Morag Stewart, Paula Gutierrez-Martinez, Lee L Rubin, Lance Davidow
Abstract: Cell preparations comprising a pooled and enriched, mononuclear apoptotic cell population, and a method of preparing this cell preparation are described. The pooled mononuclear apoptotic cell preparation may be obtained from pooled, allogeneic white blood cell fractions that are pooled prior to or following induction of apoptosis. Further, described herein are methods of use of these pooled apoptotic cell preparations for treating an immune disease, an inflammatory disease, an autoimmune disease, or infertility in a subject. For example, a pooled apoptotic cell preparation may be used to treat graft versus host disease (GVHD) in an allogeneic subject.
Abstract: Provided by the present invention are an antibody against human TIM-3 or an antigen-binding fragment thereof, and further provided are a nucleic acid molecule encoding the antibody, an expression vector for expressing the antibody and a host cell, and a method for producing the antibody. Further provided by the present invention are a pharmaceutical composition comprising the antibody or an antigen-binding fragment of the antibody, and an application of the pharmaceutical composition in the preparation of a medicine, the medicine is used for preventing and/or treating various diseases (including tumors, infectious diseases and autoimmune diseases).
Abstract: A method of treating sarcopenia comprises administering to a subject a composition comprising an anti-AGE antibody. The method may also be used for preventing or delaying the onset of cataracts, preventing or delaying the onset of loss of adipose tissue, increasing health span, and preventing or delaying the onset of lordokyphosis.
Abstract: The present invention relates to a method for the mass-production of exosome comprising a cargo protein, a vector for preparing the exosome, exosome including a cargo protein prepared by the method, and a method for loading the cargo protein to cytosol by using the exosome prepared thereby. According to the method for preparing an exosome comprising a cargo protein provided by the present invention, the exosome loaded with a cargo protein can be produced with a high yield, so that it can be used broadly in the treatment of disease using the exosome.
Type:
Grant
Filed:
May 29, 2020
Date of Patent:
January 16, 2024
Assignee:
ILIAS BIOLOGICS INC.
Inventors:
Chulhee Choi, Nambin Yim, Won Do Heo, Seung-Wook Ryu, Hojun Choi, Kyungsun Choi
Abstract: This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising heteroclitic peptides derived from the WT-1 protein.
Abstract: The invention features methods of producing compositions enriched in Tregs and methods for treating immunological disorders using these compositions. The invention also features methods for producing compositions enriched in lymphocytes and depleted of Tregs and the use of these compositions in the treatment of proliferative disorders.
Abstract: This disclosure relates generally to the field of immunological-based diagnostic assays including an assay to measure cell-mediated immunoresponsiveness. The present disclosure teaches determination of the state, progression and/or severity of disease conditions based on a subject's cell-mediated immunoresponsiveness. The assay contemplated herein is capable of integration into standard pathology architecture to provide a diagnostic reporting system and to facilitate point of care clinical management.
Abstract: The technology relates in part to methods for inducing partial apoptosis of cells that express an inducible caspase polypeptide. The technology further relates in part to methods for inducing partial apoptosis of cells that express an inducible modified caspase polypeptide, having a modified dose response curve to the multimeric ligand inducer. The technology also relates in part to methods for cell therapy using cells that express the inducible caspase polypeptide or the inducible modified caspase polypeptide, where the proportion of caspase polypeptide-expressing cells eliminated by apoptosis is related to the administered amount of the multimeric ligand inducer.
Type:
Grant
Filed:
January 3, 2020
Date of Patent:
December 12, 2023
Assignee:
Bellicum Pharmaceuticals, Inc.
Inventors:
Kevin Slawin, David Michael Spencer, Aaron Edward Foster
Abstract: The present invention provides means and methods for treating Interleukin 18 (IL-18)-associated diseases and disorders. In particular, the present invention discloses antibodies specific for free IL-18 and IL-18 Binding Protein (IL-18BP) for use in such treatments and for the diagnosis of the diseases and disorders.
Abstract: The present invention relates to a method for inducing differentiation of bone marrow cells into myeloid-derived suppressor cells (MDSCs) by treating the bone marrow cells with a toll-like receptor agonist (TLR agonist) or type I interferon, or for inducing dendritic cells from the MDSCs.
Type:
Grant
Filed:
September 28, 2018
Date of Patent:
November 7, 2023
Assignees:
Industry-Academic Cooperation Foundation, Yonsei University, Research & Business Foundation Sungkyunkwan University
Inventors:
Sung Jae Shin, Woo Sik Kim, Hong Min Kim, Kee Woong Kwon, Joo Heon Yoon, Won Jung Koh
Abstract: Described herein are methods of cell therapies. Also described herein are methods of generating donor derived T cells in an organ transplant recipient, by administering bone marrow stem cells to the organ transplant recipient about 1 to about 30 days after the organ transplant recipient receives one or more organ transplants.
Type:
Grant
Filed:
March 16, 2022
Date of Patent:
October 17, 2023
Assignee:
Ossium Health, Inc.
Inventors:
Erik J. Woods, Brian H. Johnstone, Dongsheng Gu, Aubrey Marie Sherry, Kelsey Gwen Musall, Megan Sykes, Tomoaki Kato, Jianing Fu